Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
'While higher prices may create some financial burden for patients and caregivers in the short term, uninterrupted access to treatment remains the greater priority.'
rediffGURU Nayagam PP advises young aspirants how to pick the right course and career.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
The remarkable rise of smallcaps reflects the emergence of a broad set of specialised businesses operating in industries where the sectoral tailwinds remain considerably stronger than macroeconomic headwinds, points out Debashis Basu.
Specialty chemicals maker Anupam Rasayan India Ltd has become the first company globally to commercialise Ethyl trifluoroacetate (ETFA) production using its proprietary continuous flow chemistry platform. This innovative technology offers significant advantages over traditional methods, and ETFA is a crucial component for pharmaceuticals, life sciences, and performance materials, with a global market estimated at USD 500-600 million.
The Indian banking sector is projected to experience a steady 9-13 per cent industrial credit growth in the first half of 2026, driven by capital expenditure, infrastructure development, and sectoral demand recovery, according to a Ficci-IBA survey.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
Corporate India is projected to offer salary increments ranging from 8.6 per cent to 10.2 per cent across various industries in the financial year 2026-27, primarily fuelled by a sustained demand for skilled and execution-focused talent, according to a TeamLease Services report.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Beijing clearly intends to extend the China-Myanmar Economic Corridor to Bangladesh as part of its larger Maritime Belt and Road Initiative to boost its Indian Ocean presence.
Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Indian foreign direct investment (FDI) in the United States has reached approximately USD 16.4 billion, supporting around 70,800 jobs and contributing significantly to research and development, according to US Deputy Undersecretary Brandon Remington.
Hyderabad-based SETL, a precision engineering company, has acquired a 51% majority stake in GScale Energy Private Limited, an AI Datacenter Engineering infrastructure specialist. This strategic move involves an initial investment of Rs 190 crore, with a total commitment of Rs 500 crore, marking SETL's expansion into the rapidly growing AI Datacenter sector and leveraging its expertise from pharmaceutical and chemical industries.
'They talked bad about our leaders. They said India was a dead economy. They were not sensitive to the Indian psyche.'
India's procurement of Venezuelan crude oil has picked up momentum since April and the South American nation has already emerged as the third largest oil supplier to the country.
A potential US-Iran peace deal, expected to be signed on June 19, is anticipated to ease geopolitical stress and benefit various sectors, particularly in India, with analysts suggesting investors await finer details before making significant moves.
The launch highlights the growing maturity of India's nuclear medicine ecosystem.
Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on.
American industry groups sought punitive tariffs on Indian goods at USTR hearings, while Indian officials defended the country's manufacturing growth as demand-led and WTO-compliant.
Prime Minister Narendra Modi announced that the India-UK Comprehensive Economic and Trade Agreement (CETA) will come into effect on July 15, 2026, anticipating a significant boost to bilateral trade and investment.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
A recently finalised peace deal between the US and Iran, set to be signed on June 19, is expected to significantly benefit India's economy by boosting exports to West Asia, stabilising the rupee, and easing inflationary pressures, according to exporters and experts.
Indian companies are increasingly opting for demergers, with 29 deals valued at over $40 billion in 2025 alone, marking a 10-year high, as promoters and boards recognise that markets favour focused businesses over complex conglomerates.
Karan Adani of Adani Ports & Special Economic Zone emerged as the top absolute value creator, adding Rs 2.67 trillion as the company's mcap rose from Rs 42,149 crore in March 2020 to Rs 3.09 trillion in March 2026 (7.3x) -- the largest rupee addition on the list.
Two former employees of a Delhi-based pharmaceutical firm have been booked for allegedly cheating, forging documents and impersonating to secure government tenders, including supplies to Army hospitals.
'I own a few cars that I have had specified minutely to my taste, and it does feel nice to know that there are no other vehicles like them anywhere in the world.'
Finance Minister Nirmala Sitharaman on Sunday proposed Rs 10,000 crore investment in the biopharma sector over the next five years, a move which would give a boost to the country's pharmaceuticals industry.
India's exports recorded a 13.78 per cent increase to USD 43.56 billion in April, marking the highest monthly outbound shipments in over four years, primarily driven by petroleum products. However, the trade deficit widened to a three-month high of USD 28.38 billion due to a 10 per cent rise in imports.
India's pharmaceutical exports have shown robust growth, reaching over USD 28 billion, despite global economic challenges. The sector is projected to reach USD 130 billion by 2030.
Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net profit falling 55 per cent to Rs 554.6 crore, missing consensus estimates. Despite strong growth in India and Africa, a significant decline in North American sales impacted overall performance, with the company now focusing on new product launches and regulatory filings to drive future gains.
The Beijing summit may have reduced immediate diplomatic uncertainty, but it did not resolve the deeper structural contest between the United States and China. That contest appears likely to define the coming decade, notes Varun Arya.
Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Indian benchmark equity indices, Sensex and Nifty, closed lower due to investor caution over rising bond yields, a weaker rupee, and fresh fuel price hikes, which have revived inflation concerns.
An Indian-origin couple in the UK has been sentenced for breaching a disqualification order, operating companies despite a ban imposed after tax fraud claims.
A top executive of Sigachi Industries has been arrested in connection with the explosion at its pharma plant in Telangana in June, which resulted in 54 deaths.
